GoodRx’s second quarter results were met with a negative market reaction, as the company’s revenue fell short of Wall Street’s expectations and adjusted profit matched consensus. Management attributed the underperformance largely to two external events: the accelerated Rite Aid bankruptcy, which removed a sizable number of stores from pharmacy networks, and an abrupt volume decline in one of its integrated savings programs with a major pharmacy benefit manager (PBM). CEO Wendy Barnes noted these developments “caused immediate cessation in the associated claims volume,” and highlighted the company’s ongoing efforts to recapture lost consumers and stabilize prescription transaction trends.

Is now the time to buy GDRX? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From GoodRx’s Q2 Earnings Call

• Lisa Christine Gill (JPMorgan) asked about the timeline for integrated savings program recovery and direct employer engagement; CEO Wendy Barnes said upside from new partners would mainly appear in 2026, with recent agreements supporting future growth.
• Michael Aaron Cherny (Leerink Partners) probed what drives the 30%+ pharma manufacturer solutions growth; Barnes emphasized positive ROI studies and regulatory trends favoring direct-to-patient engagement.
• John Wilson Ransom (Raymond James) inquired about the impact of cost-plus pricing on cash pay competitiveness; Barnes agreed cost-plus raised point-of-sale prices but stated it also supported pharmacy economics and long-term relationships.
• Charles Rhyee (TD Cowen) questioned the split between Rite Aid and ISP headwinds; CFO Chris McGinnis clarified the revenue impact was roughly half from each, and recapture assumptions were built into guidance.
• Stanislav Berenshteyn (Wells Fargo Securities) asked about declining Gold subscriptions and the outlook for new condition subscriptions; Barnes said early results for the erectile dysfunction product were positive and expected weight loss and hair loss offerings to drive subscriber growth.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will watch (1) how quickly GoodRx can recapture lost prescription volume from Rite Aid store closures and PBM disruptions, (2) evidence that pharma manufacturer solutions sustain 30%+ growth as more brands adopt direct-to-patient pricing, and (3) the uptake and profitability of new subscription products in conditions beyond erectile dysfunction. Continued execution on digital pharmacy integrations and employer partnerships will also be key indicators of progress.

GoodRx currently trades at $3.48, down from $4.35 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.